129 related articles for article (PubMed ID: 24756983)
1. Correlation of CXCL10, tumor necrosis factor receptor type II, and galectin 9 with disease activity in juvenile dermatomyositis.
Bellutti Enders F; van Wijk F; Scholman R; Hofer M; Prakken BJ; van Royen-Kerkhof A; de Jager W
Arthritis Rheumatol; 2014 Aug; 66(8):2281-9. PubMed ID: 24756983
[TBL] [Abstract][Full Text] [Related]
2. Endothelial and Inflammation Biomarker Profiles at Diagnosis Reflecting Clinical Heterogeneity and Serving as a Prognostic Tool for Treatment Response in Two Independent Cohorts of Patients With Juvenile Dermatomyositis.
Wienke J; Pachman LM; Morgan GA; Yeo JG; Amoruso MC; Hans V; Kamphuis SSM; Hoppenreijs EPAH; Armbrust W; van den Berg JM; Hissink Muller PCE; Gelderman KA; Arkachaisri T; van Wijk F; van Royen-Kerkhof A
Arthritis Rheumatol; 2020 Jul; 72(7):1214-1226. PubMed ID: 32103637
[TBL] [Abstract][Full Text] [Related]
3. Galectin-9 and CXCL10 as Biomarkers for Disease Activity in Juvenile Dermatomyositis: A Longitudinal Cohort Study and Multicohort Validation.
Wienke J; Bellutti Enders F; Lim J; Mertens JS; van den Hoogen LL; Wijngaarde CA; Yeo JG; Meyer A; Otten HG; Fritsch-Stork RDE; Kamphuis SSM; Hoppenreijs EPAH; Armbrust W; van den Berg JM; Hissink Muller PCE; Tekstra J; Hoogendijk JE; Deakin CT; de Jager W; van Roon JAG; van der Pol WL; Nistala K; Pilkington C; de Visser M; Arkachaisri T; Radstake TRDJ; van der Kooi AJ; Nierkens S; Wedderburn LR; van Royen-Kerkhof A; van Wijk F
Arthritis Rheumatol; 2019 Aug; 71(8):1377-1390. PubMed ID: 30861625
[TBL] [Abstract][Full Text] [Related]
4. Biomarker profiles of endothelial activation and dysfunction in rare systemic autoimmune diseases: implications for cardiovascular risk.
Wienke J; Mertens JS; Garcia S; Lim J; Wijngaarde CA; Yeo JG; Meyer A; van den Hoogen LL; Tekstra J; Hoogendijk JE; Otten HG; Fritsch-Stork RDE; de Jager W; Seyger MMB; Thurlings RM; de Jong EMGJ; van der Kooi AJ; van der Pol WL; ; Arkachaisri T; Radstake TRDJ; van Royen-Kerkhof A; van Wijk F
Rheumatology (Oxford); 2021 Feb; 60(2):785-801. PubMed ID: 32810267
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis.
Bilgic H; Ytterberg SR; Amin S; McNallan KT; Wilson JC; Koeuth T; Ellingson S; Newman B; Bauer JW; Peterson EJ; Baechler EC; Reed AM
Arthritis Rheum; 2009 Nov; 60(11):3436-46. PubMed ID: 19877033
[TBL] [Abstract][Full Text] [Related]
6. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course.
Reed AM; Peterson E; Bilgic H; Ytterberg SR; Amin S; Hein MS; Crowson CS; Ernste F; Gillespie EB
Arthritis Rheum; 2012 Dec; 64(12):4078-86. PubMed ID: 22886447
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study.
Apaz MT; Saad-Magalhães C; Pistorio A; Ravelli A; de Oliveira Sato J; Marcantoni MB; Meiorin S; Filocamo G; Pilkington C; Maillard S; Al-Mayouf S; Prahalad S; Fasth A; Joos R; Schikler K; Mozolova D; Landgraf JM; Martini A; Ruperto N;
Arthritis Rheum; 2009 Apr; 61(4):509-17. PubMed ID: 19333974
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Published Criteria for Clinically Inactive Disease in a Large Juvenile Dermatomyositis Cohort Shows That Skin Disease Is Underestimated.
Almeida B; Campanilho-Marques R; Arnold K; Pilkington CA; Wedderburn LR; Nistala K;
Arthritis Rheumatol; 2015 Sep; 67(9):2495-502. PubMed ID: 25988361
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis. Implications for diagnosis and therapy.
Kimball AB; Summers RM; Turner M; Dugan EM; Hicks J; Miller FW; Rider LG
Arthritis Rheum; 2000 Aug; 43(8):1866-73. PubMed ID: 10943878
[TBL] [Abstract][Full Text] [Related]
10. Dermatomyositis and chemokines.
Elia G
Clin Ter; 2015; 166(2):e118-21. PubMed ID: 25945444
[TBL] [Abstract][Full Text] [Related]
11. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study.
Sanner H; Kirkhus E; Merckoll E; Tollisen A; Røisland M; Lie BA; Taraldsrud E; Gran JT; Flatø B
Arthritis Care Res (Hoboken); 2010 Aug; 62(8):1103-11. PubMed ID: 20506141
[TBL] [Abstract][Full Text] [Related]
12. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications.
Pachman LM; Liotta-Davis MR; Hong DK; Kinsella TR; Mendez EP; Kinder JM; Chen EH
Arthritis Rheum; 2000 Oct; 43(10):2368-77. PubMed ID: 11037898
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity.
Bellutti Enders F; Delemarre EM; Kuemmerle-Deschner J; van der Torre P; Wulffraat NM; Prakken BP; van Royen-Kerkhof A; van Wijk F
Ann Rheum Dis; 2015 Jan; 74(1):315-7. PubMed ID: 25269830
[No Abstract] [Full Text] [Related]
14. Association between lack of angiogenic response in muscle tissue and high expression of angiostatic ELR-negative CXC chemokines in patients with juvenile dermatomyositis: possible link to vasculopathy.
Fall N; Bove KE; Stringer K; Lovell DJ; Brunner HI; Weiss J; Higgins GC; Bowyer SL; Graham TB; Thornton S; Grom AA
Arthritis Rheum; 2005 Oct; 52(10):3175-80. PubMed ID: 16200621
[TBL] [Abstract][Full Text] [Related]
15. Hsp60 in inflamed muscle tissue is the target of regulatory autoreactive T cells in patients with juvenile dermatomyositis.
Elst EF; Klein M; de Jager W; Kamphuis S; Wedderburn LR; van der Zee R; Albani S; Kuis W; Prakken BJ
Arthritis Rheum; 2008 Feb; 58(2):547-55. PubMed ID: 18240224
[TBL] [Abstract][Full Text] [Related]
16. The Vasculopathy of Juvenile Dermatomyositis: Endothelial Injury, Hypercoagulability, and Increased Arterial Stiffness.
Papadopoulou C; Hong Y; Krol P; Al Obaidi M; Pilkington C; Wedderburn LR; Brogan PA; Eleftheriou D
Arthritis Rheumatol; 2021 Jul; 73(7):1253-1266. PubMed ID: 33393715
[TBL] [Abstract][Full Text] [Related]
17. Muscle Expression of Type I and Type II Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features.
Moneta GM; Pires Marafon D; Marasco E; Rosina S; Verardo M; Fiorillo C; Minetti C; Bracci-Laudiero L; Ravelli A; De Benedetti F; Nicolai R
Arthritis Rheumatol; 2019 Jun; 71(6):1011-1021. PubMed ID: 30552836
[TBL] [Abstract][Full Text] [Related]
18. Quantitative assessments of the effects of a single exercise session on muscles in juvenile dermatomyositis.
Maillard SM; Jones R; Owens CM; Pilkington C; Woo PM; Wedderburn LR; Murray KJ
Arthritis Rheum; 2005 Aug; 53(4):558-64. PubMed ID: 16082634
[TBL] [Abstract][Full Text] [Related]
19. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.
Lovell DJ; Lindsley CB; Rennebohm RM; Ballinger SH; Bowyer SL; Giannini EH; Hicks JE; Levinson JE; Mier R; Pachman LM; Passo MH; Perez MD; Reed AM; Schikler KN; Smith M; Zemel LS; Rider LG
Arthritis Rheum; 1999 Oct; 42(10):2213-9. PubMed ID: 10524696
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.
Niewold TB; Kariuki SN; Morgan GA; Shrestha S; Pachman LM
Arthritis Rheum; 2009 Jun; 60(6):1815-24. PubMed ID: 19479879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
